El doctor Enrique Grande, nombrado profesor adjunto de la Universidad de Texas MD Anderson Houston dentro del departamento de Oncología Médica Genitourinaria Published on 11/09/2024 El nuevo profesor adjunto del centro de Houston se suma así al grupo de facultativos de MD Anderson Madrid – Hospiten que comparten este título académico en sus diversas categorías
The early detection of bladder cancer results in less invasive treatment with cure rates of 90% with long term survival Published on 23/05/2024 This is the fifth most commonly diagnosed tumour in Spain, with an incidence almost five times greater in men than in women.
Immunotherapy can benefit overall survival rates in cases of renal carcinoma in combination with adjuvant treatment Published on 03/04/2024 Renal carcinoma is one of the 15 most common tumours worldwide, affecting more than 9,000 patients every year in Spain1
The approach to thyroid cancer has become a reference model for other oncology drugs Published on 22/09/2023 The diagnosis of this pathology generally starts with the identification of nodules in the area of the neck or the joint between the collarbone and the sternum through an ultrasound followed by a biopsy.
The Head of the MD Anderson Madrid – Hospiten Medical Oncology Department presents one of the ASCO oral sessions on the treatment of genitourinary tumours Published on 05/06/2023 The IMvigor130 study, which assesses the combination of atezolizumab with chemotherapy in the first line treatment of metastatic urothelial carcinoma
Theragnostics and a multidisciplinary approach, keys to the treatment of neuroendocrine tumors Published on 10/11/2022 These are rare tumors, around 3,000 to 4,000 cases a year in this country, and they can appear in anywhere in the body
La investigación de biomarcadores en cáncer de vejiga optimiza la selección de pacientes candidatos a inmunoterapia Published on 23/09/2022 Un estudio, donde participa MD Anderson Cancer Center Madrid – Hospiten, muestra que la selección más certera de los pacientes que responderán a la inmunoterapia podría reducir los niveles de toxicidad, al evitar la administración de fármacos con reducidas probabilidades de éxito
A second medical opinion can offer a greater range of cancer treatments that can be better adapted to each patient Published on 15/06/2022 Having more information about their diagnosis is part of the patient's right to make a more informed decision about their treatment options while taking into account their particular circumstances
The construction of a neobladder, a solution used in 90% of bladder cancer operations at MD Anderson Madrid – Hospiten Published on 09/05/2022 Multidisciplinary management and rapid access to innovative therapies maximize the chances of cure and recovery for patients with bladder cancer
Immediate access to innovation in kidney cancer treatments, essential for patient survival Published on 08/03/2022 MD Anderson Madrid – Hospiten offers the possibility of access to clinical trials and surgery with the Da Vinci robot for patients with kidney cancer, one of the 15 most common tumors in Spain